AB 73: Real property: disclosure.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2016-09-24
Existing law requires certain disclosures to be made upon the transfer of residential property and prescribes the manner and form of the disclosures. Existing law provides that no cause of action arises against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property, as specified, or that an occupant of that property had or died from Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. Existing law declares the Legislatures intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property.
This bill would revise the above provisions to provide that the owner of real property, his or her agent, or an agent of a transferee of real property is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications. The bill would also delete the reference to AIDS from the declaration of legislative intent and instead refer to the HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law requires certain disclosures to be made upon the transfer of residential property and prescribes the manner and form of the disclosures. Existing law provides that no cause of action arises against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property, as specified, or that an occupant of that property had or died from Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. Existing law declares the Legislatures intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property.
This bill would revise the above provisions to provide that the owner of real property, his or her agent, or an agent of a transferee of real property is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications. The bill would also delete the reference to AIDS from the declaration of legislative intent and instead refer to the HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law requires certain disclosures to be made upon the transfer of residential property and prescribes the manner and form of the disclosures. Existing law provides that no cause of action arises against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property, as specified, or that an occupant of that property had or died from Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. Existing law declares the Legislatures intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property.
This bill would delete the prohibition against a cause of action arising for failure to disclose that an occupant of that property had or died from this virus. The bill would further revise the above provisions to specify provide that the owner of real property, his or her agent, or an agent of a transferee of real property is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications. The bill would also delete the reference to AIDS from the declaration of legislative intent and instead refer to the HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law requires certain disclosures to be made upon the transfer of residential property and prescribes the manner and form of the disclosures. Existing law provides that no cause of action arises against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property, as specified, or that an occupant of that property had or died from Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. Existing law declares the Legislatures intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property.
This bill would delete the prohibition against a cause of action arising for failure to disclose that an occupant of that property had or died from this virus. The bill would further revise the above provisions to specify that the owner of real property, his or her agent, or an agent of a transferee of real property is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with human immunodeficiency virus (HIV). (HIV) or died from AIDS-related complications. The bill would also delete the reference to AIDS from the declaration of legislative intent and instead refer to the HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law requires certain disclosures to be made upon the transfer of residential property and prescribes the manner and form of the disclosures. Existing law provides that no cause of action arises against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property, as specified, or that an occupant of that property had or died from Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. Existing law declares the Legislatures intent to occupy the field of regulation of disclosure related to deaths occuring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property.
This bill would delete the prohibition against a cause of action arising for failure to disclose that an occupant of that property had or died from this virus. The bill would also delete the reference to AIDS from the declaration of legislative intent.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law establishes the Medi-Cal program, administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law specifies the benefits provided pursuant to the program, including the purchase of prescribed drugs that are covered subject to utilization controls. Utilization controls include a requirement that the treatment provider obtain prior authorization for providing medical treatment, as specified.
This bill, to the extent permitted by federal law, would provide that if medically necessary antiretroviral drugs used in the treatment of HIV/AIDS is prescribed by a Medi-Cal beneficiarys treating provider for that purpose, and coverage for that prescribed drug is denied by a Medi-Cal managed care plan in which the beneficiary is enrolled, that denial shall be reviewed in accordance with the bill. This bill would provide that if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as specified, the beneficiary would be entitled to an automatic urgent appeal, as defined.
Existing law establishes the Medi-Cal program, administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law specifies the benefits provided pursuant to the program, including the purchase of prescribed drugs that are covered subject to utilization controls. Utilization controls include a requirement that the treatment provider obtain prior authorization for providing medical treatment, as specified.
This bill would, bill, to the extent permitted by federal law, would provide that drugs in specified therapeutic drug classes that are prescribed by a Medi-Cal beneficiarys treating provider are covered Medi-Cal benefits. The bill would require, except as specified, that a Medi-Cal managed care plan cover the drug if the treating provider demonstrates that the drug is medically necessary, not on the Medi-Cal managed care plan formulary, and consistent with federal rules and regulations for labeling and use, under which circumstances if medically necessary antiretroviral drugs used in the treatment of HIV/AIDS is prescribed by a Medi-Cal beneficiarys treating provider for that purpose, and coverage for that prescribed drug is denied by a Medi-Cal managed care plan in which the beneficiary is enrolled, that denial shall be reviewed in accordance with the bill. This bill would provide that if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as specified, the beneficiary would be entitled to an automatic urgent appeal, as defined.
Existing law establishes the Medi-Cal program, administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law specifies the benefits provided pursuant to the program, including the purchase of prescribed drugs that are covered subject to utilization controls. Utilization controls include a requirement that the treatment provider obtain prior authorization for providing medical treatment, as specified.
This bill would, to the extent permitted by federal law, provide that drugs in specified therapeutic drug classes that are prescribed by a Medi-Cal beneficiarys treating provider are covered Medi-Cal benefits. The bill would require, except as specified, that a Medi-Cal managed care plan cover the drug upon demonstration by the provider if the treating provider demonstrates that the drug is medically necessary, not on the Medi-Cal managed care plan formulary, and consistent with federal rules and regulations for labeling and use, as specified use, under which circumstances the beneficiary would be entitled to an automatic urgent appeal, as defined.
Existing law provides for establishes the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law specifies the benefits provided pursuant to the program, including the purchase of prescribed drugs that are covered subject to utilization controls. Utilization controls include a requirement that the treatment provider obtain prior authorization for providing medical treatment, as specified.
This bill would declare the intent of the Legislature to enact legislation to include specified therapeutic drug classes, as prescribed by a licensed prescriber in his or her reasonable, professional judgment, as a covered Medi-Cal benefit, to the extent permitted by federal law.
This bill would, to the extent permitted by federal law, provide that drugs in specified therapeutic drug classes that are prescribed by a Medi-Cal beneficiarys treating provider are covered Medi-Cal benefits. The bill would require, except as specified, that a Medi-Cal managed care plan cover the drug upon demonstration by the provider that the drug is medically necessary and consistent with federal rules and regulations for labeling and use, as specified.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions. Existing law specifies the benefits provided pursuant to the program, including the purchase of prescribed drugs that are covered subject to utilization controls. Utilization controls include a requirement that the treatment provider obtain prior authorization for providing medical treatment, as specified.
This bill would declare the intent of the Legislature to enact legislation to include specified therapeutic drug classes, as prescribed by a licensed prescriber in his or her reasonable, professional judgment, as a covered Medi-Cal benefit, to the extent permitted by federal law.
(a)(1)Subject to subdivision (d), an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
(A)The occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property.
(B)That an occupant of that property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications.
(2)As used in this section:
(A)Agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code.
(B)Transferee includes a purchaser, lessee, or renter of real property.
(3)No cause of action shall arise against an owner or his or her agent or any agent of a transferee for not disclosing facts pursuant to paragraph (1).
(b)It is the intent of the Legislature to occupy the field of regulation of disclosure related to either of the following:
(1)Deaths occurring upon real property.
(2)The HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)This section shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to protect HIV and AIDS patients and the HIV/AIDS community from discrimination in real property transactions that may otherwise impose severe emotional distress, it is necessary for this act to take effect immediately.
(a)(1)Subject to subdivision (d), an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
(A)The occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property.
(B)That an occupant of that property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications.
(2)As used in this section:
(A)Agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code.
(B)Transferee includes a purchaser, lessee, or renter of real property.
(3)No cause of action shall arise against an owner or his or her agent or any agent of a transferee for not disclosing facts pursuant to paragraph (1).
(b)It is the intent of the Legislature to occupy the field of regulation of disclosure related to either of the following:
(1)Deaths occurring upon real property.
(2)The HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)This section shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to protect HIV and AIDS patients and the HIV/AIDS community from discrimination in real property transactions that may otherwise impose severe emotional distress, it is necessary for this act to take effect immediately.
(a)(1)Subject to subdivision (d), an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
(A)The occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property.
(B)That an occupant of that property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications.
(2)As used in this section:
(A)Agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code.
(B)Transferee includes a purchaser, lessee, or renter of real property.
(3)No cause of action shall arise against an owner or his or her agent or any agent of a transferee for not disclosing facts pursuant to paragraph (1).
(b)It is the intent of the Legislature to occupy the field of regulation of disclosure related to either of the following:
(1)Deaths occurring upon real property.
(2)The HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)This section shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to protect HIV and AIDS patients and the HIV/AIDS community from discrimination in real property transactions that may otherwise impose severe emotional distress, it is necessary for this act to take effect immediately.
(a)(1)Subject to subdivision (d), an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
(A)The occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property.
(B)That an occupant of that property was living with human immunodeficiency virus (HIV). (HIV) or died from AIDS-related complications.
(2)As used in this section:
(A)Agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code.
(B)Transferee includes a purchaser, lessee, or renter of real property.
(b)It is the intent of the Legislature to occupy the field of regulation of disclosure related to either of the following:
(1)Deaths occurring upon real property.
(2)The HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)This section shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to protect HIV and AIDS patients and the HIV/AIDS community from discrimination in real property transactions that may otherwise impose severe emotional distress, it is necessary for this act to take effect immediately.
(a)No cause of action arises against an owner of real property or his or her agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property. As used in this section, agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code. As used in this section, transferee includes a purchaser, lessee, or renter of real property.
(b)It is the intention of the Legislature to occupy the field of regulation of disclosure related to deaths occurring upon real property in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)Nothing in this section shall be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SECTION 1.Section 1710.2 of the Civil Code is amended to read:1710.2.(a)No cause of action arises against an (1)Subject to subdivision (d), an owner of real property or his or her agent, or any agent of a transferee of real property, for the failure is not required to disclose either of the following to the transferee the occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property, or that an occupant of that property was afflicted with, or died from, Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. As used in this section, agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code. As used in this section, transferee includes a purchaser, lessee, or renter of real property. transferee, as these are not material facts that require disclosure:
(A)The occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property.
(B)That an occupant of that property was living with human immunodeficiency virus (HIV).
(2)As used in this section:
(A)Agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code.
(B)Transferee includes a purchaser, lessee, or renter of real property.
(b)It is the intention intent of the Legislature to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property. either of the following:
(1)Deaths occurring upon real property.
(2)The HIV-positive status of a prior occupant in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)Nothing in this section shall This section shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:AIDS In order to protect HIV and AIDS patients and the AIDS HIV/AIDS community require a change in state law to protect them from discrimination in real property transactions that may otherwise impose severe emotional distress. distress, it is necessary for this act to take effect immediately.(a)No cause of action arises against an owner of real property or his or her agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupants death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property, or that an occupant of that property was afflicted with, or died from, Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. property. As used in this section, agent includes any person licensed pursuant to Part 1 (commencing with Section 10000) of Division 4 of the Business and Professions Code. As used in this section, transferee includes a purchaser, lessee, or renter of real property.
(b)It is the intention of the Legislature to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property.
(c)This section shall not be construed to alter the law relating to disclosure pertaining to any other physical or mental condition or disease, and this section shall not relieve any owner or agent of any obligation to disclose the physical condition of the premises.
(d)Nothing in this section shall be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
AIDS patients and the AIDS community require a change in state law to protect them from discrimination in real property transactions that may otherwise impose severe emotional distress.
SECTION 1.This act shall be known, and may be cited as, the Patient Access to Prescribed Antiretroviral Drugs for HIV/AIDS Treatment Act.
SEC. 2.Section 14133.06 is added to the Welfare and Institutions Code, to read:14133.06.(a)It is the intent of the Legislature in enacting this section that a Medi-Cal beneficiary shall have prompt access to medically necessary antiretroviral drugs for use in the treatment of HIV/AIDS that have been approved by the federal Food and Drug Administration for that purpose, including drugs that are not on the formulary of a Medi-Cal managed care plan or that are subject to prior authorization.
(b)To the extent permitted by federal law, if a drug used in the treatment of HIV/AIDS as described in subdivision (a) is prescribed by a Medi-Cal beneficiarys treating provider for the treatment of HIV/AIDS, and coverage for that prescribed drug is denied by a Medi-Cal managed care plan in which the beneficiary is enrolled, that denial shall be reviewed in accordance with this section.
(c)(1)The denial by a Medi-Cal managed care plan of a drug prescribed for the treatment of HIV/AIDS and approved by the federal Food and Drug Administration for use in the treatment of HIV/AIDS is subject to the urgent appeal process described in paragraph (2) if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as supported in at least one of the official compendia identified in Section 1927(g)(1)(B)(i) of the federal Social Security Act (42 U.S.C. Sec. 1396r-8(g)(1)(B)(i)), and the drug is not on the formulary for the Medi-Cal managed care plan.
(2)In a case in which a plan denies coverage for a drug prescribed for the treatment of HIV/AIDS and approved by the federal Food and Drug Administration for use in the treatment of HIV/AIDS, the beneficiary shall be entitled to an urgent appeal in accordance with paragraph (1). For purposes of this section, urgent appeal means an appeal in which the beneficiary, or treatment provider with the consent of the beneficiary, requests an appeal either orally or in writing. An urgent appeal shall be resolved by the plan within 24 hours after the plan receives the request. The 24-hour period specified in this paragraph shall be in addition to any time prescribed by federal law.
This act shall be known, and may be cited as, the Prescriber Prevails Patient Access to Prescribed Antiretroviral Drugs for HIV/AIDS Treatment Act.
SEC. 2.Section 14133.06 is added to the Welfare and Institutions Code, to read:14133.06.(a)It is the intent of the Legislature in enacting this section that a Medi-Cal beneficiary shall have prompt access to medically necessary drugs for use in the treatment of the conditions specified in this section and that have been approved by the federal Food and Drug Administration for the treatment of those conditions, including drugs that are not on the formulary of the Medi-Cal managed care plan or that are subject to prior authorization.
(b)To the extent permitted by federal law, if a drug in any of the following therapeutic drug classes is prescribed by a Medi-Cal beneficiarys treating provider, that drug shall be covered under the Medi-Cal program:
(1)Antiretroviral drugs for HIV/AIDS.
(2)Antipsychotics.
(3)Antirejection drugs.
(4)Drugs used to treat seizures or epilepsy.
(c)(1)A drug is covered pursuant to this section if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as supported in at least one of the official compendia, as defined in Section 1927(g)(1)(B)(i) of the federal Social Security Act (42 U.S.C. Sec. 1396r-8(g)(1)(B)(i)), and the drug is not on the formulary for the Medi-Cal managed care plan.
(2)In a case in which a plan denies coverage for a drug prescribed under this section, the beneficiary shall be entitled to an automatic urgent appeal. For purposes of this paragraph, automatic urgent appeal means an appeal in which the plan immediately notifies the department of the denial of coverage, and the beneficiary is not required to take any further action. An automatic urgent appeal shall be resolved within 48 hours after denial by the plan. The 48-hour period specified in this paragraph shall be in addition to any time prescribed by federal law.
(3)Medi-Cal managed care plans shall continue to develop formularies and may also administer prior authorization programs for the drugs specified in subdivision (b). Providers prescribing those drugs may be required to provide the plans with requested information or clinical documentation to support prior authorization requests. The plans may continue to provide a temporary three-day supply of medication when medically necessary.
(4)Consistent with federal law, if a Medi-Cal managed care plan is unable to complete a prior authorization due to missing information or because the prescribers reasonable, professional judgment has not been adequately demonstrated, as required under this subdivision, the plan shall issue a notice of action to the provider and the beneficiary. The plan shall include in the notice of action a description of the information that is required from the provider or the beneficiary in order for the plan to complete the authorization, and the beneficiarys rights regarding appeal and fair hearing options, and independent review by the Department of Managed Health Care.
SEC. 2.Section 14133.06 is added to the Welfare and Institutions Code, to read:14133.06.(a)It is the intent of the Legislature in enacting this section that a Medi-Cal beneficiary shall have prompt access to medically necessary antiretroviral drugs for use in the treatment of HIV/AIDS that have been approved by the federal Food and Drug Administration for that purpose, including drugs that are not on the formulary of a Medi-Cal managed care plan or that are subject to prior authorization.
(b)To the extent permitted by federal law, if a drug used in the treatment of HIV/AIDS as described in subdivision (a) is prescribed by a Medi-Cal beneficiarys treating provider for the treatment of HIV/AIDS, and coverage for that prescribed drug is denied by a Medi-Cal managed care plan in which the beneficiary is enrolled, that denial shall be reviewed in accordance with this section.
(c)(1)The denial by a Medi-Cal managed care plan of a drug prescribed for the treatment of HIV/AIDS and approved by the federal Food and Drug Administration for use in the treatment of HIV/AIDS is subject to the urgent appeal process described in paragraph (2) if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as supported in at least one of the official compendia identified in Section 1927(g)(1)(B)(i) of the federal Social Security Act (42 U.S.C. Sec. 1396r-8(g)(1)(B)(i)), and the drug is not on the formulary for the Medi-Cal managed care plan.
(2)In a case in which a plan denies coverage for a drug prescribed for the treatment of HIV/AIDS and approved by the federal Food and Drug Administration for use in the treatment of HIV/AIDS, the beneficiary shall be entitled to an urgent appeal in accordance with paragraph (1). For purposes of this section, urgent appeal means an appeal in which the beneficiary, or treatment provider with the consent of the beneficiary, requests an appeal either orally or in writing. An urgent appeal shall be resolved by the plan within 24 hours after the plan receives the request. The 24-hour period specified in this paragraph shall be in addition to any time prescribed by federal law.
This act shall be known, and may be cited as, the Prescriber Prevails Act.
SEC. 2.Section 14133.06 is added to the Welfare and Institutions Code, to read:14133.06.(a)It is the intent of the Legislature in enacting this section that a prescribers reasonable, professional judgment prevails for the therapeutic drug classes specified in subdivision (b) that are not on managed care plan formularies or have prior authorization requirements. Medi-Cal beneficiary shall have prompt access to medically necessary drugs for use in the treatment of the conditions specified in this section and that have been approved by the federal Food and Drug Administration for the treatment of those conditions, including drugs that are not on the formulary of the Medi-Cal managed care plan or that are subject to prior authorization.
(b)To the extent permitted by federal law, if a drug in any of the following therapeutic drug classes is prescribed by a Medi-Cal beneficiarys treating provider, that drug shall be covered under the Medi-Cal program:
(1)Antiretroviral drugs for HIV/AIDS.
(2)Antipsychotics.
(3)Antirejection drugs.
(4)Drugs used to treat seizures or epilepsy.
(c)Except as provided in subdivision (d), and notwithstanding the establishment of a statewide outpatient drug formulary, a Medi-Cal managed care plan shall cover a drug specified in subdivision (b), regardless of whether the drug is on the plans formulary, if, upon demonstration (1)A drug is covered pursuant to this section if the treating provider demonstrates, consistent with federal law by the provider law, that the drug, in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as supported in at least one of the official compendia, as defined in Section 1927(g)(1)(B)(i) of the federal Social Security Act (42 U.S.C. Sec. 1396r-8(g)(1)(B)(i)). 1396r-8(g)(1)(B)(i)), and the drug is not on the formulary for the Medi-Cal managed care plan.
(2)In a case in which a plan denies coverage for a drug prescribed under this section, the beneficiary shall be entitled to an automatic urgent appeal. For purposes of this paragraph, automatic urgent appeal means an appeal in which the plan immediately notifies the department of the denial of coverage, and the beneficiary is not required to take any further action. An automatic urgent appeal shall be resolved within 48 hours after denial by the plan. The 48-hour period specified in this paragraph shall be in addition to any time prescribed by federal law.
(1)
(3)Medi-Cal managed care plans shall continue to develop formularies and may also administer prior authorization programs for the drugs specified in subdivision (b). Providers prescribing those drugs may be required to provide the plans with requested information or clinical documentation to support prior authorization requests. The plans may continue to provide a temporary three-day supply of medication when medically necessary.
(2)
(4)Consistent with federal law, if a Medi-Cal managed care plan is unable to complete a prior authorization due to missing information or because the prescribers reasonable, professional judgment has not been adequately demonstrated, as required under this subdivision, the plan shall issue a notice of action to the provider and the beneficiary. The plan shall include in the notice of action a description of the information that is required from the provider or the beneficiary in order for the plan to complete the authorization, and the beneficiarys rights regarding appeal and fair hearing options, and independent review by the Department of Managed Health Care.
(d)(1) If a Medi-Cal managed care plan chooses not to cover the drugs specified in subdivision (b), the drugs shall be carved out of that plan and covered on a fee-for-service basis.
(2)If a drug is carved out of a Medi-Cal managed care plan as described in paragraph (1), the plans contracted rate shall be reduced accordingly.
This act shall be known, and may be cited as, the Prescriber Prevails Act.
SEC. 2.Section 14133.06 is added to the Welfare and Institutions Code, to read:14133.06.(a)It is the intent of the Legislature in enacting this section that a prescribers reasonable, professional judgment prevails for the therapeutic drug classes specified in subdivision (b) that are not on managed care plan formularies or have prior authorization requirements.
(b)To the extent permitted by federal law, if a drug in any of the following therapeutic drug classes is prescribed by a Medi-Cal beneficiarys treating provider, that drug shall be covered under the Medi-Cal program:
(1)Antiretroviral drugs for HIV/AIDS.
(2)Antipsychotics.
(3)Antirejection drugs.
(4)Drugs used to treat seizures or epilepsy.
(c)Except as provided in subdivision (d), and notwithstanding the establishment of a statewide outpatient drug formulary, a Medi-Cal managed care plan shall cover a drug specified in subdivision (b), regardless of whether the drug is on the plans formulary, if, upon demonstration consistent with federal law by the provider that the drug, in his or her reasonable, professional judgment, is medically necessary and consistent with the federal Food and Drug Administrations labeling and use rules and regulations, as supported in at least one of the official compendia, as defined in Section 1927(g)(1)(B)(i) of the federal Social Security Act (42 U.S.C. Sec. 1396r-8(g)(1)(B)(i)).
(1)Medi-Cal managed care plans shall continue to develop formularies and may also administer prior authorization programs for the drugs specified in subdivision (b). Providers prescribing those drugs may be required to provide the plans with requested information or clinical documentation to support prior authorization requests. The plans may continue to provide a temporary three-day supply of medication when medically necessary.
(2)Consistent with federal law, if a Medi-Cal managed care plan is unable to complete a prior authorization due to missing information or because the prescribers reasonable, professional judgment has not been adequately demonstrated, as required under this subdivision, the plan shall issue a notice of action to the provider and the beneficiary. The plan shall include in the notice of action a description of the information that is required from the provider or the beneficiary in order for the plan to complete the authorization, and the beneficiarys rights regarding appeal and fair hearing options.
(d)(1) If a Medi-Cal managed care plan chooses not to cover the drugs specified in subdivision (b), the drugs shall be carved out of that plan and covered on a fee-for-service basis.
(2)If a drug is carved out of a Medi-Cal managed care plan as described in paragraph (1), the plans contracted rate shall be reduced accordingly.
SECTION 1.Section 14133.06 is added to the Welfare and Institutions Code, to read:14133.06.It is the intent of the Legislature to enact legislation to include specified therapeutic drug classes, as prescribed by a licensed prescriber in his or her reasonable, professional judgment, as a covered benefit under this chapter, to the extent permitted by federal law.
It is the intent of the Legislature to enact legislation to include specified therapeutic drug classes, as prescribed by a licensed prescriber in his or her reasonable, professional judgment, as a covered benefit under this chapter, to the extent permitted by federal law.
|
Date
|
Status
|
|---|---|
| Sep 7, 2016 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 30, 2016 | Urgency clause adopted. Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 80. Noes 0. Page 6429.). |
| Aug 30, 2016 | Urgency clause adopted. Senate amendments concurred in. To Engrossing and Enrolling. |
| Aug 25, 2016 | From committee: That the Senate amendments be concurred in. (Ayes 9. Noes 0.) (August 25). |
| Aug 24, 2016 | Joint Rule 62(a), file notice suspended. (Page 6243.) |
| Aug 24, 2016 | Joint Rule 62(a), file notice suspended. |
| Aug 24, 2016 | Re-referred to Com. on JUD. pursuant to Assembly Rule 77.2. |
| Aug 24, 2016 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 26 pursuant to Assembly Rule 77. |
| Aug 23, 2016 | Read third time. Urgency clause adopted. Passed. Ordered to the Assembly. (Ayes 39. Noes 0. Page 5265.). |
| Aug 23, 2016 | Reconsideration granted. (Ayes 39. Noes 0. Page 5265.) |
| Aug 23, 2016 | Read third time. Urgency clause adopted. Passed. Ordered to the Assembly. (Ayes 39. Noes 0. Page 5263.). |
| Aug 23, 2016 | Reconsideration granted. |
| Aug 23, 2016 | Motion to reconsider made by Senator Monning. |
| Aug 23, 2016 | Read third time. Urgency clause adopted. Passed. Ordered to the Assembly. |
| Aug 19, 2016 | Read second time. Ordered to third reading. |
| Aug 18, 2016 | Read third time and amended. Ordered to second reading. |
| Aug 16, 2016 | Read second time and amended. Ordered to third reading. |
| Aug 15, 2016 | From committee: Amend, and do pass as amended. (Ayes 6. Noes 0.) (August 9). |
| Aug 2, 2016 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on JUD. |
| Aug 1, 2016 | Re-referred to Com. on JUD. |
| Aug 1, 2016 | Re-referred to Com. on RLS. |
| Aug 1, 2016 | Withdrawn from committee. |
| Jun 30, 2016 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 29, 2016 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Feb 4, 2016 | Referred to Com. on HEALTH. |
| Jan 25, 2016 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jan 25, 2016 | Read third time. Passed. Ordered to the Senate. (Ayes 77. Noes 0. Page 3475.) |
| Jan 21, 2016 | Read second time. Ordered to third reading. |
| Jan 21, 2016 | From committee: Do pass. (Ayes 17. Noes 0.) (January 21). |
| Jan 6, 2016 | Re-referred to Com. on APPR. |
| Jan 5, 2016 | From committee chair, with author's amendments: Amend, and re-refer to Com. on APPR. Read second time and amended. |
| May 20, 2015 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| May 5, 2015 | Re-referred to Com. on APPR. |
| May 4, 2015 | Read second time and amended. |
| Apr 30, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 19. Noes 0.) (April 28). |
| Mar 17, 2015 | Re-referred to Com. on HEALTH. |
| Mar 16, 2015 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 12, 2015 | Referred to Com. on HEALTH. |
| Jan 5, 2015 | Read first time. |
| Dec 19, 2014 | From printer. May be heard in committee January 18. |
| Dec 18, 2014 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 30, 2016 | AB 73 WALDRON Concurrence - Urgency Added | Assembly Floor |
Passed |
|
| Aug 25, 2016 | With recommendation: That Senate amendments be concurred in. | Assembly Standing Committee on Judiciary |
Passed |
|
| Aug 23, 2016 | Assembly 3rd Reading AB73 Waldron By Monning Urgency Clause | Senate Floor |
Passed |
|
| Aug 23, 2016 | Assembly 3rd Reading AB73 Waldron By Monning Reconsider | Senate Floor |
Passed |
|
| Aug 23, 2016 | Assembly 3rd Reading AB73 Waldron By Monning Urgency Clause | Senate Floor |
Passed |
|
| Aug 9, 2016 | Do pass as amended | Senate Standing Committee on Judiciary |
Passed |
|
| Jan 25, 2016 | AB 73 WALDRON Assembly Third Reading | Assembly Floor |
Passed |
|
| Jan 21, 2016 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 28, 2015 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Date of Hearing: August 25, 2016
ASSEMBLY COMMITTEE ON JUDICIARY
Mark Stone, Chair
ABPCA Bill Id:AB 73
Author:Waldron – As Amended Ver:August 18, 2016
FOR CONCURRENCE
SUBJECT: Real property: disclosure
KEY ISSUE: Should existing law be clarified to affirmatively state that the owner of real property, or his or her agent, is not required to disclose to a prospective buyer or renter the HIV/AIDs Status of a previous occupant?
SYNOPSIS
This non-controversial bill clarifies existing law by affirmatively stating that the owner of real property is not required to disclose the HIV status of a previous occupant of the property, or whether the occupant had or died of AIDS, when selling, leasing, or renting a home. In the mid-1980s, in response to misconceptions about how the HIV virus was transmitted and to protect persons with HIV/AIDS from discrimination, the Legislature enacted legislation designed to free owners of real property, or their agents, from any duty to disclose to a prospective buyer or renter that an occupant of the property either had HIV or died from AIDS-related complications. However, the original legislation did not affirmatively state there was no duty to disclose this information; rather, the legislation stated that "no cause of action arises" against the owner or agent for failure to disclose such information. This bill, however, would affirmatively state that the real property owner or agent is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with human immunodeficiency virus (HIV). While existing law clearly states that there is no cause of action for failure to disclose, owners and agents reportedly remain uncertain as to whether or not there is a duty to disclose. The author contends that existing law has caused confusion among some homeowners and realtors due to the specific mention of HIV in the statute. Clearly, the intent of the original legislation was not only to state that there could be no cause of action for failure to disclose, but impliedly, that there is no duty to disclose. As a practical matter, that is, one does not have a legal "duty" if there are no consequences for not performing that duty. Be that as it may, this bill would make it abundantly clear that neither the owner of real property, nor his or her agent, is under any duty or requirement to disclose to a buyer or renter of the property that an occupant of the property had or died from HIV or AIDS, as these are not material facts that require disclosure. The bill would also specify, consistent with existing law, that no cause of action shall arise for failure to disclose such information. This bill is co-sponsored by the AIDS Project Los Angeles and the Los Angeles LGBT Center, and it is supported by the ACLU and the California Apartment Association. There is no known opposition to this bill.
SUMMARY: Specifies that the owner of real property, his or her agent, or the agent of a transferee of real property, is not required to disclose that an occupant of the property being transferred was living with human immunodeficiency virus (HIV) or died from AIDS-related complications. Specifically this bill:
- Provides that an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
- The occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date that the transferee offers to purchase, lease, or rent the real property.
- That an occupant of that property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications.
- Specifies that no cause of action shall arise against an owner or his or her agent or any agent of a transferee for not disclosing the facts described in a) and b) above.
EXISTING LAW:
- Requires the seller of real property, or his or her agent, to provide a specified disclosure statement and make specified disclosures relating to the real property before transfer of title, or close of escrow, when transferring real property. (Civil Code Sections 1102 et seq. and Sections 2079 et seq.)
- Provides that no cause of action shall arise against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence or manner of an occupant's death where the death has occurred more than three years prior the date of the transferee's offer to purchase or lease the property, or that an occupant of the property had or died from AIDS. (Civil Code Section 1710.2.)
FISCAL EFFECT: As currently in print this bill is keyed non-fiscal.
COMMENTS: In the mid-1980s, in response to rampant misconceptions about AIDS or how the HIV virus that causes it could be transmitted from one person to another, lawmakers and policy makers took various steps to combat common misconceptions, including the fear that the HIV virus could be acquired by merely touching physical objects that had been touched by a person with AIDS or HIV. With SB 284 in 1986 and SB 324 in 1987, the Legislature enacted legislation designed to free sellers or renters of real property, or their agents, from any duty to disclose to a prospective buyer or renter that an occupant of the property either had, or died from, HIV or AIDS-related complications. However, the original legislation did not affirmatively state there was no duty to disclose this information; rather, the legislation stated that "no cause of action arises" against the seller or agent for failure to disclose such information.
This bill, on the other hand, would affirmatively state that the real property owner or agent is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with, or died from, HIV or AIDS. According to the author, while existing law may clearly state that there is no cause of action for failure to disclose, many property owners and agents remain uncertain as to whether or not there is a duty to disclose. The author and co-sponsors contend that this provision of the law (Civil Code Section 1710.2) has caused confusion among some homeowners and realtors because of the specific mention of HIV within the statute. Clearly, the intent of the original legislation was not only to state that there could be no cause of action for failure to disclose; if there were no cause of action then, impliedly, there was no duty to disclose. As a practical matter, that is, one cannot be said to have a legal "duty" if there are no consequences for not performing the duty. Be that as it may, property owners and their agents reportedly remain uncertain about this; therefore, this bill would make it abundantly clear that neither the owner of real property, nor his or her agent, is under any duty or requirement to disclose that an previous occupant of the property had or died from HIV or AIDS, as these are not material facts that require disclosure. The bill would also specify, consistent with existing law, that no cause of action shall arise for failure to disclose such information.
ARGUMENTS IN SUPPORT: According to AIDS Project Los Angeles (APLA) and the Los Angeles LGBT Center, the co-sponsors of this bill, while existing law (Civil Code Section 1710.2) protects "people living with HIV from discrimination when selling or renting real estate . . . in practice, the specific mention of HIV causes confusion for many homeowners and real estate agents. In fact, many believe they are required to disclose the HIV-status of a previous occupant." The co-sponsors believe that this bill will address this confusion by clarifying the intent of the existing statute – which is "to protect people living with HIV and their families from having personal medical information mistakenly and unnecessarily revealed."
The California Apartment Association (CAA) similarly contends that "the current statute has created some confusion for property owners and realtors who have made an assumption that a disclosure is required when the previous occupant was afflicted with HIV or AIDS." CAA "believes this was not the intent of the law nor should it be."
REGISTERED SUPPORT / OPPOSITION:
Support
AIDS Project Los Angeles (co-sponsor)
Los Angeles LGBT Center (co-sponsor)
ACLU
California Apartment Association
ViiV Healthcare
Opposition
None on file
Analysis Prepared by: Thomas Clark /JUD./(916) 319-2339
CONCURRENCE IN SENATE AMENDMENTS
CSA2 Bill Id:AB 73
Author:(Waldron and Gipson)
As Amended Ver:August 18, 2016
2/3 vote. Urgency
ASSEMBLY: |
| (January 25, 2016) | SENATE: | 39-0 | (August 23, 2016) |
(vote not relevant)
COMMITTEE VOTE: | 9-0 | (August 25, 2016) | RECOMMENDATION: | concur |
(Jud.)
Original Committee Reference: HEALTH.
SUMMARY: Specifies that the owner of real property, his or her agent, or the agent of a transferee of real property, is not required to disclose that an occupant of the property being transferred was living with human immunodeficiency virus (HIV), and that no cause of action shall arise for failure to disclose such information.
The Senate amendments delete the Assembly version of this bill, and instead:
- Provide that an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
- The occurrence of an occupant's death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property.
- That an occupant of that property was living with human immunodeficiency virus (HIV) or died from AIDS-related complications.
- Specify that no cause of action shall arise against an owner or his or her agent or any agent of a transferee for not disclosing the facts in a) and b) above.
EXISTING LAW:
- Requires the seller of real property, or his or her agent, to provide a specified disclosure statement and make specified disclosures relating to the real property before transfer of title, or close of escrow, when transferring real property. (Civil Code Sections 1102 et seq. and Sections 2079 et seq.)
- Provides that no cause of action shall arise against a real property owner or agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence or manner of an occupant's death where the death has occurred more than three years prior the date of the transferee's offer to purchase or lease the property, or that an occupant of the property had or died from AIDS. (Civil Code Section 1710.2.)
FISCAL EFFECT: None
COMMENTS: In the mid-1980s, in response to rampant misconceptions about AIDS or how the HIV virus that causes it could be transmitted from one person to another, lawmakers and policy makers began to take steps to combat common misconceptions, including the fear that the HIV virus could be acquired by merely touching physical objects that had been touched by a person with AIDS or HIV. With SB 284 (Ellis), Chapter 513, Statutes of 1986, and SB 324 (Davis), Chapter 494, Statutes of 1987, the Legislature enacted legislation designed to free sellers or real property, or their agents, from any duty to disclose to a prospective buyer that an occupant of the property either had or died from AIDS. However, the original legislation did not affirmatively state there was no duty to disclosure this information; rather, the legislation stated that "no cause of action arises" against the seller or agent for failure to disclose such information. This bill, however, would affirmatively state that the real property owner or agent is not required to disclose the occurrence or manner of death of an occupant, as specified, or that an occupant of the property was living with human immunodeficiency virus (HIV). According to the author, while existing law may clearly state that there is no cause of action for failure to disclose, many sellers and their agents remain uncertain as to whether or not there is a duty to disclose. The author and co-sponsors contend that this section caused confusion among some homeowners and realtors because of the specific mention of HIV in the statute. Clearly, the intent of the original legislation was not only to state that there could be no cause of action for failure to disclose, but implicitly, because there could be no cause of action, there was impliedly no duty to disclose. As a practical matter, that is, one cannot be said to have a legal "duty" if there are no consequences for not performing the duty. Be that as it may, this bill would make it abundantly clear that neither the seller of real property, nor his or her agent, is under any duty or requirement to disclose that an occupant of the property had or died from AIDS, as these are not material facts that require disclosure. This bill would also specify, consistent with existing law, that no cause of action shall arise for failure to disclose such information.
Analysis Prepared by: Thomas Clark / JUD. / (916) 319-2334 FN: 0004930
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 73
:
SENATE JUDICIARY COMMITTEE: 6-0, 8/9/16
AYES: Jackson, Moorlach, Hertzberg, Leno, Monning, Wieckowski
NO VOTE RECORDED: Anderson
ASSEMBLY FLOOR: 77-0, 1/25/16 - See last page for vote
SOURCE: AIDS Project of Los Angeles
Los Angeles LGBT Center
DIGEST: This bill specifies that the owner of real property, his or her agent, or the agent of a transferee of real property, is not required to disclose that an occupant of the property being transferred was living with human immunodeficiency virus (HIV) or died from acquired immune deficiency syndrome (AIDS) related complications.
Senate Floor Amendments of 8/18/16 clarify that no cause of action shall arise for failure to disclose the facts specified above.
Existing law:
- Provides that all people have inalienable rights, including the right to pursue and obtain privacy. (Cal. Const., art. I, Sec. 1.)
- States that to protect the privacy of individuals who are the subject of testing for HIV, no person shall be compelled in any state, county, city, or other local civil, criminal, administrative, legislative, or other proceedings to identify or provide identifying characteristics that would identify any individual who is the subject of an HIV test, as specified. (Health & Saf. Code Sec. 120975.)
- Requires the transferor to deliver a statutory transfer disclosure statement and other disclosures as soon as practicable before transfer of title, or close of escrow, when transferring real property and manufactured homes or mobilehomes. (Civ. Code Sec. 1102.3a(a).)
- States that no cause of action arises against an owner of real property or his or her agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property, or that an occupant of that property was afflicted with, or died from, Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. (Civ. Code Sec. 1710.2(a).)
- Specifies that the above provision shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property. (Civ. Code Sec. 1710.2(d).)
This bill:
- Recasts the above provisions to state that an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
- The occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property; or
- That an occupant of that property was living HIV or died from AIDS-related complications.
- Specifies that no cause of action shall arise for failure to disclose the non-material facts specified above.
- Makes related technical and conforming changes to existing law.
Background
According to NAM (National AIDS Manual), HIV is a type of retrovirus identified in the 1980s that attacks and gradually causes damage to the human immune system.
[W]ithout treatment and care, a person with HIV is at risk of developing serious infections and cancers that a healthy immune system would fight off. Current treatment for HIV works by reducing the amount of HIV in the body so the immune system can work normally. This doesn’t get rid of HIV completely, but with the right treatment and care, someone with HIV can expect to live a long and healthy life.
. . .
AIDS [acquired immune deficiency syndrome] is the name used to describe a combination of potentially life-threatening infections and cancers, which can develop when someone’s immune system has been damaged by HIV.
. . .
Treatment with combinations of anti-HIV drugs can keep the immune system strong, and because of this the number of people who are diagnosed with AIDS has fallen. Thanks to effective HIV treatment, many people who developed AIDS are now very well and can look forward to a long and healthy life. (See http://www.aidsmap.com/hiv-basics/HIV-AIDS/page/1412437/ [as of Aug. 4, 2016].)
HIV, the virus that can lead to AIDS, is found in certain body fluids, but does not survive long outside the human body, and it cannot reproduce outside a human host. Consequently, “[y]ou cannot get HIV from kissing, by hugging, or by shaking hands with somebody with HIV – or any other normal social contact. Nor can you get HIV by being in the same place as someone with HIV, or by sharing household items such as crockery, cutlery, or bed linen,” and “HIV is not passed on by spitting, sneezing or coughing.” (See http://www.aidsmap.com/hiv-basics/Transmission/page/1412438/ [as of Aug. 4, 2016].)
The Legislature passed SB 2484 (Roberti, Chapter 498, Statutes of 1986) and SB 324 (Davis, Chapter 292, Statutes of 1987) in the 1980s to relieve transferors of property from any duty to disclose that an occupant of the property was infected with HIV. This bill recasts and clarifies those provisions by explicitly stating that the transferor of a property is not required to disclose that an occupant of the property being transferred was living with HIV or died from AIDS-related complications.
Comments
According to the author:
Existing law states the Legislature’s intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property. California Civil Code section 1710.2, which refers to real estate disclosures, says that sellers and agents are protected from a cause of action for the failure to disclose a previous occupant’s cause of death from HIV on that property that has occurred more than three years prior to the date the buyer offers to purchase, lease, or rent the real property. This section was originally written to protect people living with HIV from being discriminated against when selling or renting real estate. However, this section caused confusion for many homeowners and real estate agents because of the specific mention of HIV. This confusion leads many to believe that they are required to disclose that the previous occupant was HIV positive.
AB 73 updates the California Civil Code to remove language that stigmatizes people living with HIV and clarify that there is no requirement to disclose a previous occupant’s HIV status when selling, leasing, or renting a home.
Prior Legislation
SB 324 (Davis, Chapter 292, Statutes of 1987) provided that no cause of action arises against the owner of real property, or his or her agent, or the agent of the transferee of a property, for the failure to disclose that an occupant of that property died from the virus that causes AIDS. The bill also immunized owners of real property and their agents from causes of action based on their failure to disclose the fact or manner of the death of an occupant that occurred more than three years prior to transfer, but provided that such immunity did not extend to intentional misrepresentations concerning deaths on the property in response to a direct inquiry from a transferee.
SB 2484 (Roberti, Chapter 498, Statutes of 1986) provided that no cause of action arises against the owner of real property, or his or her agent, or the agent of the transferee of a property, for the failure to disclose that an occupant of that property was afflicted with the virus that causes AIDS.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
AIDS Project of Los Angeles (co-source)
Los Angeles LGBT Center (co-source)
American Civil Liberties Union of California
California Apartment Association
ViiV Healthcare
OPPOSITION: (Verified 8/19/16)
None received
ASSEMBLY FLOOR: 77-0, 1/25/16
AYES: Achadjian, Alejo, Travis Allen, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Campos, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dahle, Daly, Dodd, Eggman, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Roger Hernández, Holden, Irwin, Jones, Jones-Sawyer, Kim, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Quirk, Rendon, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Atkins
NO VOTE RECORDED: Dababneh, Eduardo Garcia
8/19/16 18:49:11
**** END ****
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 73
:
SENATE JUDICIARY COMMITTEE: 6-0, 8/9/16
AYES: Jackson, Moorlach, Hertzberg, Leno, Monning, Wieckowski
NO VOTE RECORDED: Anderson
ASSEMBLY FLOOR: 77-0, 1/25/16 - See last page for vote
SOURCE: AIDS Project of Los Angeles
Los Angeles LGBT Center
DIGEST: This bill specifies that the owner of real property, his or her agent, or the agent of a transferee of real property, is not required to disclose that an occupant of the property being transferred was living with human immunodeficiency virus (HIV) or died from acquired immune deficiency syndrome (AIDS) related complications.
Existing law:
- Provides that all people have inalienable rights, including the right to pursue and obtain privacy. (Cal. Const., art. I, Sec. 1.)
- States that to protect the privacy of individuals who are the subject of testing for HIV, no person shall be compelled in any state, county, city, or other local civil, criminal, administrative, legislative, or other proceedings to identify or provide identifying characteristics that would identify any individual who is the subject of an HIV test, as specified. (Health & Saf. Code Sec. 120975.)
- Requires the transferor to deliver a statutory transfer disclosure statement and other disclosures as soon as practicable before transfer of title, or close of escrow, when transferring real property and manufactured homes or mobilehomes. (Civ. Code Sec. 1102.3a(a).)
- States that no cause of action arises against an owner of real property or his or her agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property, or that an occupant of that property was afflicted with, or died from, Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. (Civ. Code Sec. 1710.2(a).)
- Specifies that the above provision shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property. (Civ. Code Sec. 1710.2(d).)
This bill:
- Recasts the above provisions to state that an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
- The occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property; or
- That an occupant of that property was living with HIV or died from AIDS-related complications.
- Makes related technical and conforming changes to existing law.
Background
According to NAM (National AIDS Manual), HIV is a type of retrovirus identified in the 1980s that attacks and gradually causes damage to the human immune system.
[W]ithout treatment and care, a person with HIV is at risk of developing serious infections and cancers that a healthy immune system would fight off. Current treatment for HIV works by reducing the amount of HIV in the body so the immune system can work normally. This doesn’t get rid of HIV completely, but with the right treatment and care, someone with HIV can expect to live a long and healthy life.
. . .
AIDS [acquired immune deficiency syndrome] is the name used to describe a combination of potentially life-threatening infections and cancers, which can develop when someone’s immune system has been damaged by HIV.
. . .
Treatment with combinations of anti-HIV drugs can keep the immune system strong, and because of this the number of people who are diagnosed with AIDS has fallen. Thanks to effective HIV treatment, many people who developed AIDS are now very well and can look forward to a long and healthy life. (See http://www.aidsmap.com/hiv-basics/HIV-AIDS/page/1412437/ [as of Aug. 4, 2016].)
HIV, the virus that can lead to AIDS, is found in certain body fluids, but does not survive long outside the human body, and it cannot reproduce outside a human host. Consequently, “[y]ou cannot get HIV from kissing, by hugging, or by shaking hands with somebody with HIV – or any other normal social contact. Nor can you get HIV by being in the same place as someone with HIV, or by sharing household items such as crockery, cutlery, or bed linen,” and “HIV is not passed on by spitting, sneezing or coughing.” (See http://www.aidsmap.com/hiv-basics/Transmission/page/1412438/ [as of Aug. 4, 2016].)
The Legislature passed SB 2484 (Roberti, Chapter 498, Statutes of 1986) and SB 324 (Davis, Chapter 292, Statutes of 1987) in the 1980s to relieve transferors of property from any duty to disclose that an occupant of the property was infected with HIV. This bill recasts and clarifies those provisions by explicitly stating that the transferor of a property is not required to disclose that an occupant of the property being transferred was living with HIV or died from AIDS-related complications.
Comments
According to the author:
Existing law states the Legislature’s intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property. California Civil Code section 1710.2, which refers to real estate disclosures, says that sellers and agents are protected from a cause of action for the failure to disclose a previous occupant’s cause of death from HIV on that property that has occurred more than three years prior to the date the buyer offers to purchase, lease, or rent the real property. This section was originally written to protect people living with HIV from being discriminated against when selling or renting real estate. However, this section caused confusion for many homeowners and real estate agents because of the specific mention of HIV. This confusion leads many to believe that they are required to disclose that the previous occupant was HIV positive.
AB 73 updates the California Civil Code to remove language that stigmatizes people living with HIV and clarify that there is no requirement to disclose a previous occupant’s HIV status when selling, leasing, or renting a home.
Prior Legislation
SB 324 (Davis, Chapter 292, Statutes of 1987) provided that no cause of action arises against the owner of real property, or his or her agent, or the agent of the transferee of a property, for the failure to disclose that an occupant of that property died from the virus that causes AIDS. The bill also immunized owners of real property and their agents from causes of action based on their failure to disclose the fact or manner of the death of an occupant that occurred more than three years prior to transfer, but provided that such immunity did not extend to intentional misrepresentations concerning deaths on the property in response to a direct inquiry from a transferee.
SB 2484 (Roberti, Chapter 498, Statutes of 1986) provided that no cause of action arises against the owner of real property, or his or her agent, or the agent of the transferee of a property, for the failure to disclose that an occupant of that property was afflicted with the virus that causes AIDS.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
AIDS Project of Los Angeles (co-source)
Los Angeles LGBT Center (co-source)
American Civil Liberties Union of California
California Apartment Association
ViiV Healthcare
None received
ASSEMBLY FLOOR: 77-0, 1/25/16
AYES: Achadjian, Alejo, Travis Allen, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Campos, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dahle, Daly, Dodd, Eggman, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Roger Hernández, Holden, Irwin, Jones, Jones-Sawyer, Kim, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Quirk, Rendon, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Atkins
NO VOTE RECORDED: Dababneh, Eduardo Garcia
8/16/16 17:33:27
**** END ****
Senator Hannah-Beth Jackson, Chair
2015-2016 Regular Session
Bill No: AB 73 (Author:Waldron)
Version: August 2, 2016
Hearing Date: August 9, 2016
Fiscal: No
Urgency: Yes
Consultant: TH
SUBJECT
Real Property: Disclosure
DESCRIPTION
This bill specifies that the owner of real property, his or her agent, or the agent of a transferee of real property, is not required to disclose that an occupant of the property being transferred was living with human immunodeficiency virus (HIV).
BACKGROUND
According to NAM (National AIDS Manual), HIV is a type of retrovirus identified in the 1980s that attacks and gradually causes damage to the human immune system.
[W]ithout treatment and care, a person with HIV is at risk of developing serious infections and cancers that a healthy immune system would fight off. Current treatment for HIV works by reducing the amount of HIV in the body so the immune system can work normally. This doesn’t get rid of HIV completely, but with the right treatment and care, someone with HIV can expect to live a long and healthy life.
. . .
AIDS [acquired immune deficiency syndrome] is the name used to describe a combination of potentially life-threatening infections and cancers, which can develop when someone’s immune system has been damaged by HIV.
. . .
Treatment with combinations of anti-HIV drugs can keep the immune system strong, and because of this the number of people who are diagnosed with AIDS has fallen. Thanks to effective HIV treatment, many people who developed AIDS are now very well and can look forward to a long and healthy life. (See http://www.aidsmap.com/hiv-basics/HIV-AIDS/page/1412437/ [as of Aug. 4, 2016].)
HIV, the virus that can lead to AIDS, is found in certain body fluids, but does not survive long outside the human body, and it cannot reproduce outside a human host. Consequently, “[y]ou cannot get HIV from kissing, by hugging, or by shaking hands with somebody with HIV – or any other normal social contact. Nor can you get HIV by being in the same place as someone with HIV, or by sharing household items such as crockery, cutlery, or bed linen,” and “HIV is not passed on by spitting, sneezing or coughing.” (See http://www.aidsmap.com/hiv-basics/Transmission/page/1412438/ [as of Aug. 4, 2016].)
The Legislature passed SB 2484 (Roberti, Ch. 498, Stats. 1986) and SB 324 (Davis, Ch. 292, Stats. 1987) in the 1980s to relieve transferors of property from any duty to disclose that an occupant of the property was infected with HIV. This bill recasts and clarifies those provisions by explicitly stating that the transferor of a property is not required to disclose that an occupant of the property being transferred was living with human immunodeficiency virus (HIV).
CHANGES TO EXISTING LAW
Existing law, the California Constitution, provides that all people have inalienable rights, including the right to pursue and obtain privacy. (Cal. Const., art. I, Sec. 1.)
Existing law states that to protect the privacy of individuals who are the subject of testing for human immunodeficiency virus (HIV), no person shall be compelled in any state, county, city, or other local civil, criminal, administrative, legislative, or other proceedings to identify or provide identifying characteristics that would identify any individual who is the subject of an HIV test, as specified. (Health & Saf. Code Sec. 120975.)
Existing law requires the transferor to deliver a statutory transfer disclosure statement and other disclosures as soon as practicable before transfer of title, or close of escrow, when transferring real property and manufactured homes or mobilehomes. (Civ. Code Sec. 1102.3a(a).)
Existing law states that no cause of action arises against an owner of real property or his or her agent, or any agent of a transferee of real property, for the failure to disclose to the transferee the occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property, or that an occupant of that property was afflicted with, or died from, Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus. (Civ. Code Sec. 1710.2(a).)
Existing law specifies that the above provision shall not be construed to immunize an owner or his or her agent from making an intentional misrepresentation in response to a direct inquiry from a transferee or a prospective transferee of real property, concerning deaths on the real property. (Civ. Code Sec. 1710.2(d).)
This bill recasts the above provisions to state that an owner of real property or his or her agent, or any agent of a transferee of real property, is not required to disclose either of the following to the transferee, as these are not material facts that require disclosure:
- the occurrence of an occupant’s death upon the real property or the manner of death where the death has occurred more than three years prior to the date the transferee offers to purchase, lease, or rent the real property; or
- that an occupant of that property was living with human immunodeficiency virus (HIV).
This bill makes related technical and conforming changes to existing law.
COMMENT
- Stated need for the bill
According to the author:
Existing law states the Legislature’s intent to occupy the field of regulation of disclosure related to deaths occurring upon real property and of AIDS in situations affecting the transfer of real property or any estate or interest in real property. California Civil Code section 1710.2, which refers to real estate disclosures, says that sellers and agents are protected from a cause of action for the failure to disclose a previous occupant’s cause of death from HIV on that property that has occurred more than three years prior to the date the buyer offers to purchase, lease, or rent the real property. This section was originally written to protect people living with HIV from being discriminated against when selling or renting real estate. However, this section caused confusion for many homeowners and real estate agents because of the specific mention of HIV. This confusion leads many to believe that they are required to disclose that the previous occupant was HIV positive.
AB 73 updates the California Civil Code to remove language that stigmatizes people living with HIV and clarify that there is no requirement to disclose a previous occupant’s HIV status when selling, leasing, or renting a home.
- Clarifying disclosure duties regarding HIV status
Existing law seeks to protect real property owners with HIV from having to disclose their medical condition to prospective purchasers of their property by stating that no cause of action arises for the failure to disclose that an occupant of the property was afflicted with, or died from, Human T-Lymphotropic Virus Type III/ Lymphadenopathy-Associated Virus. However, the phrasing of this provision and the “specific mention of HIV causes confusion for many homeowners and real estate agents,” according to the AIDS Project of Los Angeles, a co-sponsor of this bill. The AIDS Project states that,” [i]n fact, many people believe they are required to disclose the HIV-positive status of a previous occupant,” thereby defeating the protective intent of this disclosure restriction.
This bill would rephrase the existing disclosure restriction to state instead that an owner of real property “is not required to disclose . . . [t]hat an occupant of that property was living with human immunodeficiency virus (HIV),” noting that HIV status is not a material fact to a real estate transaction requiring disclosure. This bill would also, according to the AIDS Project, “remove outdated and stigmatizing language referring to HIV and bring the code up to date with current medical terminology.” With the proposed changes in phrasing, this bill should clarify that sellers of real property with HIV are not required to disclose their medical condition to potential purchasers, thereby protecting the privacy interest such sellers have in controlling the dissemination of their personal medical information.
- Amendment regarding AIDS-related complications
While the changes proposed to existing law in this bill would clarify that a property occupant’s HIV status is not a material condition requiring disclosure during the sale or transfer of real property, it may not be clear that an occupant’s death from AIDS-related complications is likewise not subject to disclosure. The author offers the following amendment to clarify that an owner of real property, his or her agent, or any agent of a transferee of real property, has no duty to disclose that an occupant of the property being transferred died from AIDS-related complications.
Author’s Amendment:
On page 3, line 28, after “(HIV),” insert: “or died from AIDS-related complications”
Support: American Civil Liberties Union of California; California Apartment Association
Opposition: None Known
HISTORY
Source: AIDS Project of Los Angeles; Los Angeles LGBT Center
Related Pending Legislation: None Known
Prior Legislation:
SB 324 (Davis, Ch. 292, Stats. 1987) provided that no cause of action arises against the owner of real property, or his or her agent, or the agent of the transferee of a property, for the failure to disclose that an occupant of that property died from the virus that causes acquired immune deficiency syndrome. This bill also immunized owners of real property and their agents from causes of action based on their failure to disclose the fact or manner of the death of an occupant that occurred more than three years prior to transfer, but provided that such immunity did not extend to intentional misrepresentations concerning deaths on the property in response to a direct inquiry from a transferee.
SB 2484 (Roberti, Ch. 498, Stats. 1986) provided that no cause of action arises against the owner of real property, or his or her agent, or the agent of the transferee of a property, for the failure to disclose that an occupant of that property was afflicted with the virus that causes acquired immune deficiency syndrome.
Prior Vote: Prior votes not relevant.
**************
SENATE COMMITTEE ON HEALTH
Senator Ed Hernandez, O.D., Chair
BILL NO: AB 73
AUTHOR: | Waldron | ||
VERSION: | January 5, 2016 | ||
HEARING DATE: | June 29, 2016 | ||
CONSULTANT: | Scott Bain | ||
SUBJECT: Patient Access to Prescribed Antiretroviral Drugs for HIV/AIDS Treatment Act
SUMMARY:
Requires the denial by a Medi-Cal managed care plan of a non-formulary drug prescribed for the treatment of HIV/AIDS that is approved by the federal Food and Drug Administration for use in the treatment of HIV/AIDS to be subject to an urgent appeal process established by this bill, if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the federal labeling and use rules and regulations.
Existing law:
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which basic health care services are provided to qualified low-income persons.
- Requires the mandatory enrollment of specified Medi-Cal beneficiaries into Medi-Cal managed care plans.
- Requires a Medi-Cal managed care plan that has prescription drugs as one of its benefits and that enters into a contract with DHCS to ensure the timely and efficient processing of authorization requests for drugs, when prescribed for plan enrollees, that are covered under the terms of the plan’s contract with DHCS and which require prior authorization from the plan, by providing both of the following:
- A response within 24 hours or one business day to a request for prior authorization made by telephone or other telecommunication device; and,
- The dispensing of at least a 72-hour supply of a covered outpatient drug in an emergency situation.
- Requires, pursuant to regulation, Medi-Cal applicants or beneficiaries to have the right to a state hearing (known as a “fair hearing”) if dissatisfied with any action or inaction of the county department, DHCS or any person or organization acting in behalf of the county or DHCS relating to Medi-Cal eligibility or benefits.
- Requires health plans licensed under the Knox-Keene Act (Medi-Cal plans, with the exception of county organized health systems [COHS] and PACE plans are required to be Knox-Keene licensed) to do all of the following:
- Establish and maintain a grievance system approved by the Department of Managed Health Care (DMHC), under which enrollees may submit their grievances to the plan. Requires an expedited plan review of grievances for cases involving an imminent and serious threat to the health of the patient, including, but not limited to, severe pain, potential loss of life, limb, or major bodily function;
- Maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary non-formulary prescription drug; and,
- Provide an enrollee with the opportunity to seek an independent medical review (IMR) whenever health care services have been denied, modified, or delayed by the plan, or by one of its contracting providers, if the decision was based in whole or in part on a finding that the proposed health care services are not medically necessary.
This bill:
- Requires, to the extent permitted by federal law, if a drug used in the treatment of HIV/AIDS is prescribed by a Medi-Cal beneficiary’s treating provider for the treatment of HIV/AIDS, and coverage for that prescribed drug is denied by a Medi-Cal managed care plan in which the beneficiary is enrolled, that denial to be reviewed in accordance with this bill.
- Requires the denial by a Medi-Cal managed care plan of a non-formulary drug prescribed for the treatment of HIV/AIDS that is approved by the federal Food and Drug Administration (FDA) for use in the treatment of HIV/AIDS to be subject to an urgent appeal process if the treating provider demonstrates, consistent with federal law, that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with the FDA’s labeling and use rules and regulations, as supported in at least one of the official compendia identified in federal Medicaid law.
- Requires a beneficiary to be entitled to an urgent appeal in a case in which a plan denies coverage for a drug prescribed for the treatment of HIV/AIDS and approved by the FDA for use in the treatment of HIV/AIDS.
- Defines an “urgent appeal” as an appeal in which the beneficiary, or treatment provider with the consent of the beneficiary, requests an appeal either orally or in writing.
- Requires an urgent appeal to be resolved by the plan within 24 hours after the plan receives the request. Requires the 24-hour period to be in addition to any time prescribed by federal law.
- States legislative intent in enacting this bill that a Medi-Cal beneficiary have prompt access to medically necessary antiretroviral drugs for use in the treatment of HIV/AIDS that have been approved by the federal FDA for that purpose, including drugs that are not on the formulary of a Medi-Cal managed care plan or that are subject to prior authorization.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, this bill will result in a likely minor one-time increase in administrative costs in MCMC, and for DHCS state administrative staff. Ongoing costs are likely to be fairly minor. All costs are General Fund/federal funds.
PRIOR VOTES:
Assembly Floor: | 77 - 0 |
Assembly Appropriations Committee: | 17 - 0 |
Assembly Health Committee: | 19 - 0 |
COMMENTS:
- Author’s statement. According to the author, formularies and step-therapy programs are not always sufficient to treat certain vulnerable populations. The federal government enacted Medicare Part D, which included six protected classes of therapeutic drugs. These categories and classes of drugs meet two criteria: (1) where restrictions on that class would have major or life threatening consequences and/or must be taken for life; and (2) where there is a significant need for disease or disorder to be treated by multiple drugs within a specified class. New pharmaceuticals and treatments are emerging rapidly, while insurance formularies do not have the capacity to keep up. In the meantime, patient care is being affected and individuals are losing access to receive the best pharmaceuticals that may control their condition sooner rather than later. Antiretroviral Drugs for HIV/AIDS Treatment Act would avoid drug resistance, spread of disease transmission, etc. Current formulary restrictions have multiple appeals processes patients have to go through. Step therapy correspondingly delays the patient from obtaining the most suitable drug combinations for their case. This bill merely allows Medi-Cal beneficiaries to use an expedited 24 hour appeal process that would give them prompt access to medically necessary drugs for Antiretroviral Drugs for HIV/AIDS Treatment.
- Medi-Cal coverage of HIV/AIDS medication and appeal rights in managed care. The 2016-17 DHCS budget assumes average monthly enrollment in Medi-Cal of over 14 million individuals, of whom nearly three-fourths will enroll in Medi-Cal managed care plans. By contract, Medi-Cal managed care plans are required to cover prescription drugs except for those drugs which are “carved out” and reimbursed through fee-for-service (FFS) Medi-Cal (“carved out” drugs are typically costly). Plans are contractually required to submit to DHCS a complete formulary, and to report changes to the formulary to DHCS upon request and on an annual basis. A plan’s formulary is required to be “comparable” to the Medi-Cal FFS list of contract drugs, with “comparable” defined as the plan’s formulary must contain drugs which represent each mechanism of action sub-class within all major therapeutic categories of prescription drugs included in the Medi-Cal FFS List of Contract Drugs. Medi-Cal managed care plans (and their contracting pharmacy benefit managers) use formularies, prior authorization and utilization controls to control costs, ensure appropriate utilization and obtain rebates from drug manufacturers. Medi-Cal managed care plans are required to meet state law, federal law and contractual provisions relating to prescription drug coverage and appeal rights. This includes an expedited process for the plan grievance process for cases involving an imminent and serious threat to the health of the enrollee, and through the Department of Social Services (DSS) fair hearing process.
DHCS indicates HIV/AIDS drugs listed in the Medi-Cal Provider Manuals are “carved out” of most Medi-Cal care plans and are instead covered by Medi-Cal Fee-For-Service (FFS). This includes Medi-Cal managed care plans in the two-plan model counties, geographic managed care, county organized health system (COHS) and primary care case management arrangements. Exceptions to the “carve out” are two COHS plans (CalOptima and Health Plan of San Mateo), and three specialty programs also carve in some or all drugs in (AIDS Healthcare Foundation has a subset of HIV/AIDS drugs carved-in to managed care, while Senior Care Action Network (SCAN) and the Program for All-Inclusive Care for the Elderly have all HIV/AIDS drugs carved-in. DHCS indicates it has not received complaints regarding health plans denying coverage for HIV/AIDS medications.
- Prior legislation. AB 68 (Waldron of 2015) would have required a Medi-Cal beneficiary to be entitled to an automatic urgent appeal, as defined, when a Medi-Cal managed care plan denies coverage for a drug prescribed for the treatment of seizures and epilepsy that is approved by the FDA for the use in the treatment of seizures and epilepsy if the patient’s treating provider demonstrates that in his or her reasonable, professional judgment, the drug is medically necessary and consistent with FDA labeling and use rules and regulations, as supported in at least one of the official compendia, and the drug is not on the formulary of the Medi-Cal managed care plan. AB 68 was vetoed by Governor Brown. In this his veto message, the Governor stated “health plans are already required to have effective up-to-date drug formularies and expedited appeal processes to cover situations when health care services, including epilepsy drugs, are denied.” Governor Brown stated he believed “establishing a separate urgent appeal for this specific medical condition is unnecessary”.
- Support. AIDS Healthcare Foundation (AHF) writes in support that providers of medical care to persons with HIV/AIDS often grapple with cost containment measures that can interfere with the provider’s decision about the best drug treatment for a particular patient. However, ultimately a degree of deference must be paid to the clinical decision by the provider. Moreover, the patient is generally in need of swift introduction of the drug in order to have a meaningful impact on the patient’s medical condition. AHF concludes that while bill would ensure that the plan maintains authority to make the ultimate decision, the urgent appeal process elevates the denial to a degree that ensures a more timely and hopefully more scrutinized decision.
- Opposition. The Local Health Plans of California (LHPC) writes in opposition that, while
LHPC agrees that consumers should be able to access medically necessary medications, they do not believe a special process for one set of drugs is necessary. In addition, Medi-Cal health plans already have processes in place for expedited appeals. LHPC also notes that HIV/AIDS drugs are carved out for most of the Medi-Cal plans and provided through FFS Medi-Cal, and as a result, they are uncertain whether this bill will have any practical effect.
- Policy question. Are denials of HIV/AIDS medications and current appeal timeframes a problem? In most areas of the state, HIV/AIDS drugs are “carved out” of Medi-Cal managed care and are instead reimbursed through the Medi-Cal FFS program, and DHCS indicates it has not had complaints regarding Medi-Cal managed care plan denials of HIV/AIDS medications.
SUPPORT AND OPPOSITION:
Support: AIDS Healthcare Foundation
California Life Sciences Association
Positive Resource Center
Retired Public Employees Association
Sunburst Projects
Two individuals
Oppose: California Association of Health Plans
Local Health Plans of California
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 73
Author:(Waldron)
As Amended Ver:January 5, 2016
Majority vote
Committee | Votes | Ayes | Noes |
Health | 19-0 | Bonta, Maienschein, Bonilla, Burke, Chávez, Chiu, Gomez, Gonzalez, Roger Hernández, Lackey, Nazarian, Patterson, Ridley-Thomas, Rodriguez, Santiago, Steinorth, Thurmond, Waldron, Wood | |
Appropriations | 17-0 | Gomez, Bigelow, Bloom, Bonilla, Bonta, Calderon, Chang, Daly, Eggman, Gallagher, Eduardo Garcia, Holden, Jones, Quirk, Wagner, Weber, Wood |
|
SUMMARY: Establishes the Patient Access to Prescribed Antiretroviral Drugs for human immunodeficiency virus (HIV) / acquired immunodeficiency syndrome (AIDS) Treatment Act which establishes an urgent appeal process if a Medi-Cal managed care (MCMC) plan denies coverage for HIV/AIDS drugs that are prescribed by a treating physician. Specifically, this bill:
- Provides that the denial by a MCMC plan of a drug prescribed for the treatment of HIV/AIDS is subject to the urgent appeal process if the treating provider demonstrates that the drug is medically necessary and consistent with the federal Food and Drug Administration's (FDA) labeling and use rules and regulations, and the drug is not on the formulary for the MCMC plan.
- Requires a MCMC plan to resolve an appeal within 24 hours after the plan receives an oral or written appeal from the beneficiary or treatment provider. Specifies that the 24-hour period is in addition to any time prescribed by federal law.
- States legislative intent for a Medi-Cal beneficiary to have prompt access to medically necessary antiretroviral drugs for use in the treatment of HIV/AIDS, including drugs that are not on the formulary of a MCMC plan or that are subject to prior authorization.
EXISTING LAW:
- Establishes in federal law the federal Medicaid program to provide comprehensive health benefits to low income persons. Establishes the Medi-Cal program as California’s Medicaid program, administered by the Department of Health Care Services (DHCS).
- Requires states, under the federal Medicaid law, to have a drug use review program for covered outpatient prescription drugs, to ensure drugs are appropriate, medically necessary, and not likely to result in adverse medical effects. Federal law requires the program to assess data on drug use against predetermined standards, consistent with specified factors, including compendia.
- Provides a schedule of benefits provided in the Medi-Cal program, including prescription drug benefits.
- Authorizes the DHCS to establish utilization controls for any Medi-Cal services as long as the controls are reasonably related to the purpose of establishing them. Allows the utilization controls include prior authorization, pre- and post-service audits, limitations on the number of services and review pursuant to professional standards.
- Provides that any prescription drug approved by the FDA for the treatment of AIDS or an AIDS-related condition is automatically approved for placement on the contract list of Medi-Cal drugs. Allows the DHCS to apply utilization controls and conditions placement on the contract list on the manufacturer signing a rebate agreement with the federal Centers for Medicare and Medicaid Services.
- Excludes from managed care, by administrative guidance of DHCS, specified prescription drugs including those for HIV/AIDS and antipsychotics.
FISCAL EFFECT: According to the Assembly Appropriations Committee, this bill will result in a likely minor one-time increase in administrative costs in MCMC, and for DHCS state administrative staff. Ongoing costs are likely to be fairly minor. All costs are General Fund/federal funds.
COMMENTS: The intent of this bill is to shorten the time frame for urgent appeals when coverage for HIV/AIDS drugs is denied through MCMC.
Medicaid (Medi-Cal in California) is a federal-state program that pays for medical assistance for low-income individuals and families. Although pharmacy coverage is an optional benefit under federal Medicaid law, all states currently cover outpatient prescription drugs for all categorically eligible individuals and most other enrollees in their Medicaid programs. Most state Medicaid programs have adopted preferred drug lists (PDL, also called formularies), making any medication not deemed preferred subject to prior authorization. States use prior authorization, in conjunction with a PDL, to encourage the prescribing of the most clinically appropriate and cost-effective drug within a specific therapeutic drug category. Under federal law, non-preferred products must be made available through a review process that must provide a response within 24 hours and allow for a 72-hour supply of the drug in emergency situations.
Medi-Cal is one of the largest drug purchasers in the state. The program spends about $4 billion on prescription drugs, including indirect expenditures through payment to managed care plans and direct expenditures in fee for service and for prescription drugs that are "carved out" of managed care. Carved out means that the state pays directly for the drug rather than indirectly through a capitated or fixed rate payment to a MCMC plan. Examples of drugs that are carved out include HIV/AIDS drugs, psychiatric drugs and blood factor. According to the DHCS, only five of the 22 managed care plan contracts require coverage for HIV/AIDS drugs and HIV/AIDS drugs are carved out for the remaining plans.
Medi-Cal currently has a process in place to appeal coverage denials, both in managed care and fee-for-service. The expedited appeal process under the managed care system, including denials for HIV/AIDS drugs, is three business days or 72 hours.
It should be noted that the prior version of this bill is broader in scope as to the types of drugs that an urgent appeal process would apply to (Antiretroviral drugs for HIV/AIDS, antipsychotics, antirejection drugs and drugs used to treat seizures or epilepsy) and required the appeal to be resolved within 48 hours after denial. This bill was subsequently amended in the Assembly Appropriations Committee to limit its application to HIV/AIDS drugs and requires the urgent appeal process to be resolved within 24 hours.
The AIDS Health Care Foundation states in support that the urgent appeal process elevates the denial to a degree that ensures a timelier and more scrutinized decision.
Opponents of the prior, broader version of this bill, including Health Access California, state that MCMC already has appeal and exception processes in place to provide consumers access to medically necessary drugs. Health Access support standards for formularies and appeal processes that assure the scientific evidence and clinically based standards of care as well as the needs of the individual consumer are taken into account.
Analysis Prepared by: Rosielyn Pulmano / HEALTH / (916) 319-2097 FN: 0002581
Date of Hearing: May 20, 2015
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Jimmy Gomez, Chair
ABPCA Bill Id:AB 73
Author:(Waldron) – As Amended Ver:January 5, 2016
Policy Committee: | Health | Vote: | 19 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill creates an expedited review process that applies if a Medi-Cal managed care plan denies coverage of a prescription drug used to treat HIV/AIDS.
The expedited review, which must be resolved by a plan within 24 hours, applies in cases where the drug is not on a plan formulary and a physician demonstrates medical necessity and consistency with federal guidelines.
FISCAL EFFECT:
This bill will result in a likely minor one-time increase in administrative costs in Medi-Cal managed care, and for DHCS state administrative staff. Ongoing costs are likely to be fairly minor. All costs are GF/federal.
COMMENTS:
- Purpose. The intent of this bill is to shorten the time frame for urgent appeals when coverage for HIV/AIDS drugs is denied through Medi-Cal managed care.
- Background. Many Medi-Cal enrollees receive health care through Medi-Cal managed care plans, which are private or locally or regionally administered public entities that contract with the state to manage the health care services of beneficiaries. Contracts between the state and the plan govern the specific products and services for which managed care plans must pay. Certain Medi-Cal covered services are carved out from managed care plan contracts, meaning the plan does not pay for them. Selected drugs in certain classes are generally carved out; these classes include HIV/AIDS drugs, detoxification and dependency treatment drugs, blood factor, and psychiatric drugs. Providing HIV drugs in this manner has allowed the state to leverage its size for greater rebates. For these drugs, instead of seeking reimbursement from plans, providers are directed to bill the Medi-Cal FFS system. Five of 22 managed care plan contracts require coverage for HIV/AIDS drugs, while HIV/AIDS drugs are carved out for the remaining plans. Enrollment in the five plans that cover HIV/AIDS drugs makes up less than 9% of the enrollment in Medi-Cal managed care, according to November 2015 figures.
Medi-Cal has processes in place to appeal coverage denials, both in managed care and in fee-for-service. The current time frame in managed care for an urgent appeal is 72 hours.
- Related Legislation.
- AB 68 (Waldron) was very similar to this bill but applied to epilepsy drugs. The bill was vetoed, with a message stating, "This bill would grant a Medi-Cal beneficiary the right to an urgent appeal when a Medi-Cal managed care plan denies coverage for a drug prescribed for the treatment of epilepsy. The health plans are already required to have effective up-to-date drug formularies and expedited appeal processes to cover situations when health care services, including epilepsy drugs, are denied. I believe establishing a separate urgent appeal for this specific medical condition is unnecessary."
- AB 1814 (Waldron) of 2014 implemented a "prescriber prevails" approach to various drug classes in Medi-Cal, whereby a prescriber's medical judgment would prevail over a health plan denial. AB 1814 was held on the Assembly Appropriations Suspense file.
- Staff Comments. This bill does not appear to address the veto message to AB 68, a very similar bill. It also sets up a drug-specific appeals process, which increases administrative costs, for uncertain benefit. Specifically, this bill applies an urgent appeal process for coverage denials of drugs that most plans are not required to cover in the first place. The existence of such appeals for plans not obligated to cover HIV/AIDS drugs appear to provide no benefit.
For the few and smaller plans to which the urgent appeal would logically apply, while a theoretical individual could receive a quicker response to an appeal of a coverage denial under this bill, staff is not in possession of data documenting a problem with timeliness of access to HIV/AIDS drugs for these Medi-Cal enrollees, nor proof the current 72-hour time frame is inadequate or causes harm, nor a reasoned defense of why HIV/AIDS drugs should be singled out in the fashion proposed by this bill.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
AB 73
Page 5
Date of Hearing: May 20, 2015
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Jimmy Gomez, Chair
AB 73
(Waldron) – As Amended May 4, 2015
Policy Committee: |
Health |
Vote: |
19 - 0 |
|
|
|
|
|
|
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill establishes the "Prescriber Prevails Act," specifying access requirements for certain drug classes covered by the Medi-Cal program and creating an urgent appeal process. Specifically, this bill:
Requires, if any drug from a specified therapeutic drug class is prescribed by a Medi-Cal beneficiary’s provider, the drug to be covered in the Medi-Cal program.
Specifies the affected drug classes are antiretrovirals for AIDS/HIV, antipsychotics, anti-rejection drugs, and drugs used to treat seizures or epilepsy.
Requires a Medi-Cal managed care plan to cover a drug in the named drug classes if prescribed by a beneficiary's provider. Requires the provider to demonstrate reasonable professional judgment, the drug is medically necessary, and it is consistent with the federal Food and Drug Administration (FDA) labeling and use rules and regulations as described in at least one of the official compendia named in federal law.
Provides that if a Medi-Cal managed care plan chooses not to cover the specified drugs, the drugs are to be carved out of the plan and covered on a fee-for-service basis and the plan's contracted rate shall be reduced accordingly.
Requires managed care plans to continue to develop and authorizes plans to administer formularies and prior authorization programs for the specified drugs.
FISCAL EFFECT:
Unknown costs and potential lost revenues, ranging from zero cost if this bill had no impact on the provision of pharmaceuticals in Medi-Cal, to millions of dollars annually (GF/federal) if the policy was implemented more liberally to allow greater prescriber control. Cost could vary dramatically depending on how this policy was operationalized. Policies and procedures would have to be clarified by DHCS, and the ease with which prescribed medications are available despite their non-preferred status would directly impact costs.
For example, if stricter limits were placed on a managed care plan's ability to conduct utilization review for these drug categories, there would likely be significant cost pressure on Medi-Cal managed care rates for pharmaceutical benefits. This bill could lead to increased Medi-Cal costs in several ways: higher prices for drugs, reduced revenue from federal and state-negotiated rebates, and reduced revenue from the state's managed care tax if drugs were carved out of managed care.
The bill specifies the use of formularies and prior authorization is allowable in managed care, but not in the fee-for-service (FFS) Medi-Cal. Antiretroviral drugs for HIV/AIDS and antipsychotics are carved out of managed care and provided exclusively through FFS Medi-Cal. Restrictions on prior authorization poses significant fiscal risk as it appears to allows prescribers to bypass the state's preferred drug list for FFS Medi-Cal as long as certain criteria are met.
Finally, the marketplace dynamics for various drug classes, prescriber behavior, and how pharmaceutical manufacturers respond to the market conditions created by this bill would also influence long-term costs.
Unknown, likely minor, potential increased administrative costs for FFS Medi-Cal, and cost pressure to managed care, for an additional number of appeals.
Unknown, likely minor, administrative costs to DHCS to adjust managed care rates if plans choose not to cover antirejection and drugs used to treat seizures or epilepsy.
Unknown offsetting cost savings, to the extent the bill is implemented robustly, in individual cases where prescribers' chosen medication prevents other medical complications. Such offsets, if any, would likely be a small percentage of increased costs.
COMMENTS:
Purpose. According to the author, this bill strengthens the doctor and patient relationship by legislating that a doctor's professional and reasonable judgment prevails, for purposes of specific and therapeutic drug classes within the Medi-Cal program. The author argues new pharmaceuticals and treatments are emerging rapidly and individuals are losing access to pharmaceuticals that may best control their condition.
Background. Drug benefits are provided through FFS Medi-Cal delivery system, and through managed care. Managed care enrollees generally get their drugs through their managed care plan, which often subcontracts with a pharmaceutical benefits manager for provision of the drug benefit. Some drugs are carved out of managed care and only offered through the FFS system. Both managed care plans and the state maintain separate lists of preferred drugs, or formularies, and impose utilization controls on drugs not contained on the formulary. The most common controls include prior authorization (a request to a plan for coverage of a drug, which must be approved in order to fill a prescription) and step therapy (where the patient must try a different, often less expensive or more proven, drug before being prescribed the drug of choice). Utilization controls function in a variety of ways but are generally designed to impose friction between the prescribing of a drug and the filling of a prescription, offering the health plan the ability to examine cost-effectiveness and clinical appropriateness.
This bill would require FFS Medi-Cal and managed care plans to cover drugs for which a prescriber prescribes a drug in a manner consisted with FDA guidelines for use of the drug, and for which the prescriber demonstrates reasonable professional judgment that the drug is medically necessary.
Current Protections. Plans, and FFS Medi-Cal, are required to pay for all drugs deemed medically necessary, regardless of the formulary. Patients can contest denials of service through various means, including the state fair hearing/grievance process and through independent medical review. 2013 data indicates there were an estimated 550 annual state fair hearings held specific to prescription drug issues, out of a total of 5.8 million managed care enrollees, a rate of about one in 10,500 enrollees.
Drug Classes Affected. The specific drug classes to which this bill would apply are for conditions that are clinically complex, for which prescribing physicians are often specialists with advanced knowledge of the conditions being treated. They are also among the most expensive drugs. The fact this bill only applies to drugs listed on a compendia offers some protection, but compendia also include various grades of evidence. Off-label use may be supported by compendia. According to individuals with expertise in managing pharmacy benefits, there are potential concerns about undermining the ability of health plans or the state to conduct utilization review for these drug classes. Cost and clinical concerns for these drug classes are noted below.
Anticonvulsants are marketed and often used for conditions other than epilepsy and seizure disorders. The bulk of utilization review for anticonvulsants is directed to off-label use. In addition, a number of new drugs are in the development pipeline at this time, meaning costs for this category are projected to grow. This bill does not specify it applies to anticonvulsants only when used for treating seizure disorders.
Antipsychotics. There are significant concerns about off-label use. This is a drug class that has benefited significantly from the availability of generic substitutes. Generic versions of former "blockbuster drugs" can be 20-30% or as much as 80%-90% cheaper than drugs with patent protection. To the extent this bill undermines the ability to use generic substitutes, significant additional costs could be incurred.
Antiretrovirals. More expensive single-tablet regimens that are marketed and patent-protected without offering significant clinical benefit over generic formulations are of concern in this drug class.
Support. Biotechnology firms and the California Chronic Care Coalition support this bill, noting individuals who require specific medications are forced to wait while they and their physicians are forced to wade through red tape and sometimes are forced to suffer with inadequate or contraindicated medications
Opposition. The California Association of Health Plans (CAHP) opposes this bill, arguing it minimizes the role of care coordination plans employ to investigate safer alternatives and to help identify appropriate and inappropriate prescribing.
Staff Comments. This bill addresses an inherent tension between the state's interest in cost-effective provision of health care services and clinical oversight, and a prescriber's professional judgment on what will be optimal for each of his or her patients. The essential questions are whether these opposing concerns are appropriately balanced, and whether current policies and practices result in patient harm and the denial of needed care in a timely way.
Under current law, the state, health plans, and pharmaceutical benefit managers attempt to balance the medical needs of the patient and prescriber preferences with the provision of affordable benefits that meet clinical standards of appropriate care. In so doing, utilization review controls, such as prior authorization and step therapy, are employed. Prior authorization, for example, is not only employed to contain costs, but to allow a clinical review to ensure medication is prescribed appropriately and to allow consideration of safer alternatives. In some instances, inappropriate prescribing can be identified. Staff notes a "prescriber prevails" policy may help certain patients in individual cases, but also has a potential for unintended consequences that could increase costs without providing a benefit to patients. For example, it may remove safeguards that prevent overprescribing or inappropriate prescribing.
The actual operation of a "prescriber prevails" law as it pertains to the Medi-Cal program is unclear and would likely have to be clarified through regulation. The ease and convenience of the process to document medical necessity, and how much it deviates from the state's current process, would have a direct impact on drug utilization and costs. For example, if the very act of prescribing a drug that meets the FDA's labeling and use requirements is deemed adequate to meet medical necessity, there would likely be large utilization and cost impacts. To the extent additional controls are put in, it would have a lesser effect on utilization and cost.
Technical note. This bill essentially allows managed care plans to choose which drugs they will cover, and requires FFS Medi-Cal to cover them if the managed care plan doesn’t. However, managed care plans are required to cover drugs that are medically necessary, subject to certain authorization procedures. The application of prescriber prevails in these cases would need to be clarified.
Suggested Amendments. The author indicates the bill is simply intended to speed up the prior authorization review process to allow more prompt access to prescribed medications. If this is the case, and if the turnaround time is indeed unacceptable, staff suggests removing provisions related to coverage, medical necessity, and provider judgment altogether, and instead amend the bill to address the state FFS program and managed care contractual requirements related to timeline for prior authorization. Since medically necessary drugs are already covered pursuant to existing law and regulations, provided the prescriber demonstrates medical necessity in the required manner, addressing the timeline should be adequate to accomplish the intent.
Related Legislation.
AB 73 (Waldron), also being heard today, is similar to this bill and applies to four drug classes, including anticonvulsants.
AB 374 (Nazarian), pending on the Suspense File of this committee, specifies requirements with which health plan step therapy regimens must comply.
Prior Legislation.
AB 1814 (Waldron) of 2014 was similar to AB 73 and was held on this committee's Suspense File.
AB 889 (Frazier) of 2013 prohibited a health plan from requiring an enrollee to try and fail on more than two medications before allowing the enrollee access to the medication, or generically equivalent drug, as specified. This bill was held on the Senate Appropriations Committee suspense file.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
AB 73
Page 6
Date of Hearing: April 28, 2015
ASSEMBLY COMMITTEE ON HEALTH
Rob Bonta, Chair
AB 73
(Waldron) – As Amended March 16, 2015
SUBJECT: Prescriber Prevails Act.
SUMMARY: Establishes that a prescriber’s reasonable professional judgment prevails over the policies and utilization controls of the Medi-Cal program, including the utilization controls of a Medi-Cal managed care plan, in prescribing a pharmaceutical from specified therapeutic drug classes. Specifically, this bill:
Requires, if any drug from a specified therapeutic drug class is prescribed by a Medi-Cal beneficiary’s provider, the drug to be covered in the Medi-Cal program.
Specifies the affected drug classes are antiretrovirals for AIDS/HIV, Hepatitis C drugs, antipsychotics, immunosuppressants for anti-rejection, and epilepsy/anti-convulsants.
Requires a Medi-Cal managed care plan to cover a drug in the named drug classes if prescribed by a beneficiary's provider. Requires the provider to demonstrate reasonable professional judgment and that the drug is medically necessary and consistent with the federal Food and Drug Administration (FDA) labeling and use rules and regulations as described in at least one of the official compendia named in federal law.
Provides that if a Medi-Cal managed care plan chooses not to cover the specified drugs, the drugs are to be carved out of the plan and covered on a fee-for-service basis and requires the plan's contracted rate to be reduced accordingly.
EXISTING LAW:
Establishes in federal law the federal Medicaid program to provide comprehensive health benefits to low income persons.
Establishes the Medi-Cal program as California’s Medicaid program.
Requires states, under the federal Medicaid law, to have a drug use review program for covered outpatient prescription drugs, to ensure drugs are appropriate, medically necessary, and not likely to result in adverse medical effects. Federal law requires the program to assess data on drug use against predetermined standards, consistent with specified factors, including compendia.
Provides a schedule of benefits provided in the Medi-Cal program, including prescription drug benefits.
Authorizes the Department of Health Care Services (DHCS) to establish utilization controls for any Medi-Cal services as long as the controls are reasonably related to the purpose of establishing them. Allows the utilization controls include prior authorization, pre- and post-service audits, limitations on the number of services and review pursuant to professional standards.
Provides that any prescription drug approved by the FDA for the treatment of AIDS or an AIDS-related condition is automatically approved for placement on the contract list of Medi-Cal drugs. Allows the DHCS to apply utilization controls and conditions placement on the contract list on the manufacturer signing a rebate agreement with the federal Centers for Medicare and Medicaid Services (CMS).
Provides that any prescription drug approved by the FDA for the treatment of cancer is automatically approved for placement on the contract list of Medi-Cal drugs. Conditions placement on the contract list on the manufacturer signing a rebate agreement with CMS.
Excludes from managed care, by administrative guidance of DHCS, specified prescription drugs including those for HIV/AIDS and antipsychotics.
FISCAL EFFECT: This bill has not been analyzed by a fiscal committee.
COMMENTS:
PURPOSE OF THIS BILL. The author explains that this bill, the Prescriber Prevails Act, strengthens the doctor and patient relationship by legislating that a doctor's reasonable, professional judgment prevails for specific, protected therapeutic drug classes within the Medi-Cal program. According to the author, current formulary restrictions have multiple appeals processes patients have to go through and step therapy correspondingly delays the patient from obtaining the most suitable drug combinations for their case. The author notes that as more people move onto Medi-Cal managed care plans, we are essentially growing a two-tier system of healthcare, those who can afford private insurance plans have doctors who may have more time to work through the existing preauthorization processes to attain a higher tier drug for their patients. However, those in vulnerable low-income situations are seeing their doctors most likely in clinics, where doctors are short on time and do not have the resources, i.e. staff, time, etc. to follow up on pre-authorization appeals. The author concludes that prescriber prevails levels the playing field for access to medically necessary drugs for low income patients with serious, chronic or life threatening conditions by shortening the pre-auth process for Medi-Cal doctors.
MEDICAID BACKGROUND. Medicaid is a federal-state program that pays for medical assistance for low-income individuals and families. Although pharmacy coverage is an optional benefit under federal Medicaid law, all states currently cover outpatient prescription drugs for all categorically eligible individuals and most other enrollees in their Medicaid programs.
Most state Medicaid programs have adopted preferred drug lists (PDL, also called formularies), making any medication not deemed preferred subject to prior authorization. States use prior authorization, in conjunction with a PDL, to encourage the prescribing of the most clinically appropriate and cost-effective drug within a specific therapeutic drug category. Under federal law, non-preferred products must be made available through a review process that must provide a response within 24 hours and allow for a 72-hour supply of the drug in emergency situations. The complexity of the prior authorization process determines the extent to which it encourages trials of preferred medications first (i.e., step therapy).
Step therapy requirements under Medicaid programs vary by state and by the prescribed drug or medical condition. Some states have broad step therapy requirements for program participants. For example, Pennsylvania has step therapy requirements for a wide variety of drugs, including protein pump inhibitors, anticonvulsants, anti-depressants, and others. Other states have narrower requirements. Georgia requires insureds to fail on two older forms of antipsychotic medications before receiving newer antipsychotic agents. Indiana has a step therapy requirement for anti-hypertensives (i.e., drugs used to address high blood pressure).
According to the federal CMS, a compendium is a listing of FDA-approved drugs and biologics. A compendium includes a summary of the pharmacologic characteristics of each drug or biological, and may include information on dosage as well as recommended or endorsed uses in specific diseases. A recent change in federal law allows the Secretary of the federal Department of Health and Human Services to revise the statutory list of compendia as appropriate for identifying medical accepted indications for drugs used in an anti-cancer chemotherapeutic regimen in Medicare. Federal regulations establish a process for listing compendia for determining medically accepted uses of drugs in anti-cancer treatment, including a formal written request for changes to the list of compendia, publishing the list of the requests and soliciting public comment, considering the compendium’s attainment of the Medicare coverage advisory committee’s recommended desirable characteristics of compendia, and considering the compendium’s grading of evidence. Federal Medicaid law requires a drug use review program. The program is required to assess data on drug use against pre-determined standards, consistent with peer-reviewed medical literature and three statutorily listed compendia.
PRESCRIPTION DRUGS IN MEDI-CAL. Medi-Cal is one of the largest drug purchasers in the state. The program spends about $4 billion on prescription drugs, including indirect expenditures through payment to managed care plans and direct expenditures in fee for service and for prescription drugs that are “carved out” of managed care. Carved out means that the state pays directly for the drug rather than indirectly through a capitated or fixed rate payment to a Medi-Cal managed care plan.
Drug spending has declined dramatically with the federal government taking greater financial responsibility with the advent of Medicare Part D drug coverage. California used to pay the prescription drug costs of dual eligibles, those individuals who were on Medi-Cal and Medicare. However, the spending on the remainder of beneficiaries has continued to rise at a rapid rate.
Facing significantly rising costs, the federal and state governments have grappled with various cost control measures. California, to help manage costs, has established a formulary for the fee-for service program. The formulary is not binding on Medi-Cal managed care plans, each of which creates their own formulary. A variety of utilization tools also are used. These include limiting prescriptions to six per month, although many beneficiaries receive more but only after a prior authorization has been approved. Frequent and high cost prescription drug users can be identified and case management interventions can be used if appropriate to reduce drug costs.
Another tool to help reign in the high costs of prescription drugs are the rebate programs. The federal government collects a rebate from prescription drug manufacturers. Manufacturers must pay a rebate to the federal government or Medicaid will not cover their prescription drug. California has been a national leader in the drug rebate program, being one of the first states to negotiate with manufacturers a “supplemental rebate” program. The program is so named because the rebate is a supplement to the federal rebate program. Manufacturers must agree to pay the state to have their prescription drug placed on a preferred drug list which usually means the drugs are available without prior authorization. At one time the state received over a billion dollars annually in net revenues through supplemental rebates. The implementation of Part D has led to significant decreases. In addition, with the increase in managed care, the state no longer bears the direct cost of paying for prescription drugs so supplemental rebates have declined more.
NEW YORK PROVIDER PREVAILS LAW. In 2011, New York changed the process by which 4 million Medicaid recipients obtain prescription drug coverage. The pharmacy benefit was “carved in” to Manage Care instead of a fee for service program. This change resulted in patients losing many protections and has led to confusion, lack of uniformity in coverage and, in some cases, denial of critical medications.
Patient advocates, health care providers and many members of the New York State Legislature began fighting to restore certain patient protections. Those protections including a comprehensive drug formulary, standardization of drug benefits, and maintaining the prescriber’s authority to decide what medicine a patient needs, frequently referred to as “prescriber prevails” In 2012, the advocacy effort resulted in restoration of “prescriber prevails” for atypical antipsychotics in the 2012-13 Executive Budget (effective January 1, 2013). Later in 2013, the prescriber prevails provision was restored for all drug classes.
DRUG CLASSES. A drug class is a group of drugs that have something in common. They are similar in some way, but they are not identical. A drug also belongs to one or more drug classes. Drugs can be in a class with other drugs for several reasons:
The drugs are related by their chemical structure;
The drugs work in the same way; or,
The drugs are used for the same purpose.
Drug class grouping then are fairly narrow. Drugs from a variety of classes are used to treat these specific diseases.
SUPPORT. Supporters states that this bill would provide that drugs in specified therapeutic drug classes that are prescribed by a Medi-Cal beneficiary’s treating provider are covered Medi-Cal benefits, given that the drug is medically necessary and consistent with federal rules and regulations for labeling and use. They note that all too often individuals who require specific medications are forced to wait while they and their physicians are forced to wade through red tape and sometimes are forced to suffer with inadequate or contraindicated medications.
OPPOSITION. The California Association of Health Plans (CAHP) opposes this bill because it does not consider the role of health plans and pharmaceutical benefit manager’s roles to ensure that the medical needs of enrollees are met and only considers the physician’s explanation for the medication. They argue this approach completely minimizes the role of care coordination that plans employ to investigate safer alternatives and to help identify appropriate and inappropriate prescribing. CAHP also argues that the existing framework of prior authorization, pharmacy benefit managers, clinical protocols and independent medical review currently all work together to assist Medi-Cal plans in managing the quality and efficacy of services and medications.
Health Access California opposes this bill because the approach in this bill eliminates the ability of the Medi-Cal program to bargain over drugs costs. They point out that since 1999 California has had a Medi-Cal formulary which has saved the state literally billions of dollars while providing consumers the drugs they need. Health Access also argues that the bill goes too far in its reliance on physician judgment as the sole determinant of what a patient needs, particularly in an environment in which Pharmaceutical manufacturers continue to engage in aggressive marketing of their products. Health Access also points out that under current law, the consumer has the right to medically necessary prescriptions.
RELATED LEGISLATION. AB 68 (Waldron) establishes that a prescriber’s reasonable professional judgment prevails over the policies and utilization controls of the Medi-Cal program, including the utilization controls of a Medi-Cal managed care plan, in prescribing a pharmaceutical that is in the seizure or epilepsy drug class. AB 68 was heard in this Committee on April 21 and passed out on a 19-0 vote with amendments and is in process before going to the Assembly Appropriations Committee.
PREVIOUS LEGISLATION.
AB 1814 (Waldron) of 2014 was very similar to this bill. AB 1814 was held on the Assembly Appropriations Suspense file.
AB 889 (Frazier) of 2013 prohibits a health plan from requiring an enrollee to try and fail on more than two medications before allowing the enrollee access to the medication, or generically equivalent drug, as specified. AB 889 was held on the Senate Appropriations Committee suspense file.
AB 369 (Huffman) of 2012 would have prohibited carriers that restrict medications for the treatment of pain, pursuant to step therapy or fail-first protocol, from requiring a patient to try and fail on more than two pain medications before allowing the patient access to the pain medication, or generically equivalent drug, as defined, prescribed by the prescribing provider, as defined. AB 369 was vetoed by Governor Brown, who stated:
While I sympathize with the author's good intentions, I am not convinced that this bill strikes the right balance between physician discretion and health plan or insurer oversight. A doctor's judgment and a health plan's clinical protocols both have a role in ensuring the prudent prescribing of pain medications. Independent medical reviews are available to resolve differences in clinical judgment when they occur, even on an expedited basis.
AB 1826 (Huffman) of 2010 would have required an insurer or health plan that covers prescription drug benefits to provide coverage for a drug that has been prescribed for the treatment of pain without first requiring the enrollee or insured to use an alternative drug or product. AB 1826 died on the Senate Appropriations Committee Suspense File.
PROPOSED AMENDMENT.
AB 68, which was similar to this bill was amended by this Committee to eliminate the strict provider prevails provisions. The Committee’s concerns were that bypassing the utilization controls of the plan may result in significant additional costs for the plan and perhaps for a patient. The alternative approach the committee chose was an expedited review by the plan, perhaps something along the lines of an automatic urgent appeal to be resolved within 48 hours. This time was in addition to any other time frames allowed in current state and federal laws.
This bill should clarify that it refers to drugs used to treat Medi-Cal beneficiaries that are diagnosed with these specific diseases. Currently the bill refers to broad groups of drug classes that are used to treat the specific named disease but also encompasses many drugs and drug classes, including pharmaceuticals which have uses beyond the treatment of the named disease. For example, anticonvulsants, or antiseizure medications, an important class of drugs for the treatment of epilepsy are increasingly used to treat bipolar disorder because of their effectiveness as a mood stabilizer. Given the language of the bill, a prescription to treat bipolar disorder with an anticonvulsant would be subject to the provisions of the prescriber prevailing over a plan’s formulary or other utilization controls. A mood stabilizer from another class of drugs would not be, which could distort prescribing decisions.
REGISTERED SUPPORT / OPPOSITION:
Support
American Nurses Association\California
Biocom
California Chronic Care Coalition
California Healthcare Institute
Mental Health America of California
Opposition
California Association of Health Plans
Health Access California
Analysis Prepared by: Roger Dunstan / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Judiciary
Assembly Floor
Assembly Standing Committee on Appropriations
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):